Human Genome, GSK Dodge Lupus-Drug Suicide Suit

Law360, New York (March 26, 2013, 7:40 PM EDT) -- A Maryland federal judge on Tuesday dismissed a consolidated securities class action accusing Human Genome Sciences Inc. and GlaxoSmithKline PLC of concealing suicide risks associated with lupus drug Benlysta, saying the plaintiffs had failed to show the companies purposefully hid reported suicides from investors.

U.S. District Judge Roger W. Titus said the facts of the case more plausibly showed that the companies had either “acted innocently or, at most, negligently” in not disclosing that that three patients had killed themselves while taking Benlysta during clinical trials,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.